Ligand binding properties of human galanin receptors

References

• Baldwin JM. 1993. The probable arrangement of the helices in G protein-coupled receptors. EMBO J 12:1693–1703.
   PubMed Web of Science ®Google Scholar
• Baldwin JM. 1994. Structure and function of receptors coupled to G proteins. Curr Opin Cell Biol 6:180–190.
   PubMed Web of Science ®Google Scholar
• Bedecs K, Langel Ü, Bartfai T. 1995. Metabolism of galanin and galanin (1-16) in isolated cerebrospinal fluid and spinal cord membranes from rat. Neuropeptides 29:137–143.
   PubMed Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, 2000. The protein data bank. Nucleic Acids Res 28:235–242.
   PubMed Web of Science ®Google Scholar
• Bernsel A, Viklund H, Hennerdal A, Elofsson A. 2009. TOPCONS: Consensus prediction of membrane protein topology. Nucleic Acids Res 37:W465–W468.
   PubMed Web of Science ®Google Scholar
• Berthold M, Kahl U, Juréus A, Kask K, Nordvall G, Langel U, 1997. Mutagenesis and ligand modification studies on galanin binding to its GTP-binding-protein-coupled receptor GalR1. Eur J Biochem/FEBS 249:601–606.
   PubMedGoogle Scholar
• Branchek TA, Smith KE, Gerald C, Walker MW. 2000. Galanin receptor subtypes. Trends Pharmacolog Sci 21:109–117.
   PubMed Web of Science ®Google Scholar
• Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SGF, Thian FS, Kobilka TS, 2007. High-resolution crystal structure of an engineered human beta2-adrenergic G protein–coupled receptor. Science (NY) 318:1258–1265.
   PubMed Web of Science ®Google Scholar
• Church WB, Jones KA, Kuiper DA, Shine J, Iismaa TP. 2002. Molecular modelling and site-directed mutagenesis of human GALR1 galanin receptor defines determinants of receptor subtype specificity. Protein Engineer 15:313–323.
   PubMedGoogle Scholar
• Clément M, Martin SS, Beaulieu M-E, Chamberland C, Lavigne P, Leduc R, 2005. Determining the environment of the ligand binding pocket of the human angiotensin II type I (hAT1) receptor using the methionine proximity assay. J Biologic Chem 280:27121–27129.
   PubMed Web of Science ®Google Scholar
• De Lano W. 2002. The Pymol molecular graphics system.
   Google Scholar
• Dundas J, Ouyang Z, Tseng J, Binkowski A, Turpaz Y, Liang J. 2006. CASTp: Computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucleic Acids Res 34:W116–W118.
   PubMed Web of Science ®Google Scholar
• Ericson E, Ahlenius S. 1999. Suggestive evidence for inhibitory effects of galanin on mesolimbic dopaminergic neurotransmission. Brain Res 822:200–209.
   PubMed Web of Science ®Google Scholar
• Eswar N, Webb B, Marti-Renom MA, Madhusudhan MS, Eramian D, Shen M-Y, 2007. Comparative protein structure modeling using MODELLER. Curr Protoc Prot Sci/ edit board Coligan JE, Chapt. 2, Unit 2.9.
   PubMedGoogle Scholar
• Evans H, Baumgartner M, Shine J, Herzog H. 1993. Genomic organization and localization of the gene encoding human preprogalanin. Genomics 18:473–477.
   PubMed Web of Science ®Google Scholar
• Fathi Z, Cunningham AM, Iben LG, Battaglino PB, Ward SA, Nichol KA, 1997. Cloning, pharmacological characterization and distribution of a novel galanin receptor. Brain Res Mol Brain Res 51:49–59.
   PubMedGoogle Scholar
• Fisone G, Wu CF, Consolo S, Nordström O, Brynne N, Bartfai T, 1987. Galanin inhibits acetylcholine release in the ventral hippocampus of the rat: Histochemical, autoradiographic, in vivo, and in vitro studies. Proc Natl Acad Sci USA 84:7339–7343.
   PubMed Web of Science ®Google Scholar
• Florén A, Land T, Langel Ü. 2000. Galanin receptor subtypes and ligand binding. Neuropeptides 34:331–337.
   PubMed Web of Science ®Google Scholar
• Florén A, Sollenberg U, Lundström L, Zorko M, Stojan J, Budihna M, 2005. Multiple interaction sites of galnon trigger its biological effects. Neuropeptides 39:547–558.
   PubMed Web of Science ®Google Scholar
• Fritze O, Filipek S, Kuksa V, Palczewski K, Hofmann KP, Ernst OP. 2003. Role of the conserved NPxxY(x)5,6F motif in the rhodopsin ground state and during activation. Proc Natl Acad Sci USA 100:2290–2295.
   PubMed Web of Science ®Google Scholar
• Fuxe K, Jansson A, Diaz-Cabiale Z, Andersson A, Tinner B, Finnman UB, 1998. Galanin modulates 5-hydroxytryptamine functions. Focus on galanin and galanin fragment/5-hydroxytryptamine1A receptor interactions in the brain. Annals NY Acad Sci 863:274–290.
   PubMed Web of Science ®Google Scholar
• Gales C. 2000. Mutation of Asn-391 within the conserved NPXXY motif of the cholecystokinin B receptor abolishes Gq protein activation without affecting its association with the receptor. J Biolog Chem 275:17321–17327.
   PubMed Web of Science ®Google Scholar
• Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, 2004. Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Medicinal Chem 47:1750–1759.
   PubMed Web of Science ®Google Scholar
• Hökfelt T, Xu ZQ, Shi TJ, Holmberg K, Zhang X. 1998. Galanin in ascending systems. Focus on coexistence with 5-hydroxytryptamine and noradrenaline. Annals NY Acad Sci 863:252–263.
   PubMed Web of Science ®Google Scholar
• Kask K, Berthold M, Kahl U, Juréus A, Nordvall G, Langel U, 1998. Mutagenesis study on human galanin receptor GalR1 reveals domains involved in ligand binding. Annals NY Acad Sci 863:78–85.
   PubMed Web of Science ®Google Scholar
• Kehr J, Yoshitake T, Wang F-H, Razani H, Gimenez-Llort L, Jansson A, 2002. Galanin is a potent in vivo modulator of mesencephalic serotonergic neurotransmission. Neuropsychopharmacology 27:341–356.
   PubMed Web of Science ®Google Scholar
• Konkel MJ, Packiarajan M, Chen H, Topiwala UP, Jimenez H, Talisman IJ, 2006. Amino substituted analogs of 1-phenyl-3-phenylimino-2-indolones with potent galanin Gal3 receptor binding affinity and improved solubility. Bioorgan Medicin Chem Lett 16:3950–3954.
   PubMed Web of Science ®Google Scholar
• Krishna AG, Menon ST, Terry TJ, Sakmar TP. 2002. Evidence that helix 8 of rhodopsin acts as a membrane-dependent conformational switch. Biochemistry 41:8298–8309.
   PubMed Web of Science ®Google Scholar
• Krogh A, Larsson B, von Heijne G, Sonnhammer EL. 2001. Predicting transmembrane protein topology with a hidden Markov model: Application to complete genomes. J Molec Biol 305:567–580.
   PubMed Web of Science ®Google Scholar
• Kuteeva E, Hökfelt T, Wardi T, Ögren SO. 2008. Galanin, galanin receptor subtypes and depression-like behaviour. Cellular Molec Life Sci 65:1854–1863.
   PubMed Web of Science ®Google Scholar
• Laplante F, Crawley JN, Quirion R. 2004. Selective reduction in ventral hippocampal acetylcholine release in awake galanin-treated rats and galanin-overexpressing transgenic mice. Regulat Peptides 122:91–98.
   PubMedGoogle Scholar
• Lassmann T, Sonnhammer ELL. 2005. Kalign – an accurate and fast multiple sequence alignment algorithm. BMC Bioinform 6:298.
   PubMed Web of Science ®Google Scholar
• Lawrence CB, Fraley GS. 2010. Galanin-like peptide: Neural regulator of energy homeostasis and reproduction. EXS 102:263–280.
   PubMedGoogle Scholar
• Lengauer T, Rarey M. 1996. Computational methods for biomolecular docking. Current Opin Struct Biol 6:402–406.
   PubMed Web of Science ®Google Scholar
• Liu HX, Brumovsky P, Schmidt R, Brown W, Payza K, Hodzic L, 2001. Receptor subtype-specific pronociceptive and analgesic actions of galanin in the spinal cord: Selective actions via GalR1 and GalR2 receptors. Proc Natl Acad Sci USA 98:9960–9964.
   PubMed Web of Science ®Google Scholar
• Lu X, Lundström L, Bartfai T. 2005. Galanin (2-11) binds to GalR3 in transfected cell lines: Limitations for pharmacological definition of receptor subtypes. Neuropeptides 39:165–167.
   PubMed Web of Science ®Google Scholar
• Lundström L, Elmquist A, Bartfai T, Langel U. 2005. Galanin and its receptors in neurological disorders. Neuromolec Med 7:157–180.
   PubMed Web of Science ®Google Scholar
• Lundström L, Sollenberg UE, Bartfai T, Langel U. 2007. Molecular characterization of the ligand binding site of the human galanin receptor type 2, identifying subtype selective interactions. J Neurochem 103:1774–1784.
   PubMed Web of Science ®Google Scholar
• Melo F, Sánchez R, Sali A. 2002. Statistical potentials for fold assessment. Protein Sci 11:430–448.
   PubMed Web of Science ®Google Scholar
• Morris MB, Ralston GB, Biden TJ, Browne CL, King GF, Iismaa TP. 1995. Structural and biochemical studies of human galanin: NMR evidence for nascent helical structures in aqueous solution. Biochemistry 34:4538–4545.
   PubMed Web of Science ®Google Scholar
• Murakami M, Kouyama T. 2008. Crystal structure of squid rhodopsin. Nature 453:363–367.
   PubMed Web of Science ®Google Scholar
• Nordström O, Melander T, Hökfelt T, Bartfai T, Goldstein M. 1987. Evidence for an inhibitory effect of the peptide galanin on dopamine release from the rat median eminence. Neurosci Lett 73:21–26.
   PubMed Web of Science ®Google Scholar
• Ohman A, Lycksell PO, Juréus A, Langel U, Bartfai T, Gräslund A. 1998. NMR study of the conformation and localization of porcine galanin in SDS micelles. Comparison with an inactive analog and a galanin receptor antagonist. Biochemistry 37:9169–9178.
   PubMed Web of Science ®Google Scholar
• Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, 2000. Crystal structure of rhodopsin: A G protein-coupled receptor. Science (NY) 289:739–745.
   PubMed Web of Science ®Google Scholar
• Parthiban M, Shanmughavel P. 2007. Three dimensional modeling of N-terminal region of galanin and its interaction with the galanin receptor. Bioinformation 2:119–125.
   PubMedGoogle Scholar
• Probst WC, Snyder LA, Schuster DI, Brosius J, Sealfon SC. 1992. Sequence alignment of the G-protein coupled receptor superfamily. DNA Cell Biol 11:1–20.
   PubMed Web of Science ®Google Scholar
• Rasmussen SGF, Choi H-J, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, 2007. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 450:383–387.
   PubMed Web of Science ®Google Scholar
• Robinson JK. 2004. Galanin and cognition. Behav Cognit Neurosci Rev 3:222–242.
   PubMedGoogle Scholar
• Robinson JK, Bartfai T, Langel Ü. 2006. Galanin/GALP receptors and CNS homeostatic processes. CNS Neurolog Disorders Drug Targets 5:327–334.
   PubMedGoogle Scholar
• Runesson J, Saar I, Lundström L, Järv J, Langel U. 2009. A novel GalR2-specific peptide agonist. Neuropeptides 43:187–192.
   PubMed Web of Science ®Google Scholar
• Runesson J, Sollenberg UE, Jurkowski W, Yazdi S, Eriksson EE, Elofsson A, 2010. Determining receptor-ligand interaction of human galanin receptor type 3. Neurochem Int 57:804–811.
   PubMed Web of Science ®Google Scholar
• Saar K, Mazarati AM, Mahlapuu R, Hallnemo G, Soomets U, Kilk K, 2002. Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proc Natl Acad Sci USA 99:7136–7141.
   PubMed Web of Science ®Google Scholar
• Sautel M, Martinez R, Munoz M, Peitsch MC, Beck-Sickinger AG, Walker P. 1995. Role of a hydrophobic pocket of the human Y1 neuropeptide Y receptor in ligand binding. Molec Cellular Endocrinol 112:215–222.
   PubMed Web of Science ®Google Scholar
• Schwartz TW. 1994. Locating ligand-binding sites in 7TM receptors by protein engineering. Current Opin Biotechnol 5:434–444.
   PubMedGoogle Scholar
• Sjödin P, Holmberg SKS, Akerberg H, Berglund MM, Mohell N, Larhammar D. 2006. Re-evaluation of receptor-ligand interactions of the human neuropeptide Y receptor Y1: A site-directed mutagenesis study. Biochem J 393:161–169.
   PubMed Web of Science ®Google Scholar
• Strnad J, Hadcock JR. 1995. Identification of a critical aspartate residue in transmembrane domain three necessary for the binding of somatostatin to the somatostatin receptor SSTR2. Biochem Biophys Res Communic 216:913–921.
   PubMed Web of Science ®Google Scholar
• Swanson CJ, Blackburn TP, Zhang X, Zheng K, Xu Z-QD, Hökfelt T, 2005. Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. Proc Natl Acad Sci USA 102:17489–17494.
   PubMed Web of Science ®Google Scholar
• Teodoro ML, Phillips GN Jr, Kavraki LE. 2001. Molecular docking: A problem with thousands of degrees of freedom. IEEE Int Conf Robotics Automat 960–966.
   Google Scholar
• Wang S, Hashemi T, He C, Strader C, Bayne M. 1997. Molecular cloning and pharmacological characterization of a new galanin receptor subtype. Molec Pharmacol 52:337–343.
   PubMed Web of Science ®Google Scholar
• Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards PC, Henderson R, 2008. Structure of a beta1-adrenergic G-protein-coupled receptor. Nature 454: 486–491.
   PubMed Web of Science ®Google Scholar
• Wiesenfeld-Hallin Z, Xu X-J, Crawley JN, Hökfelt T. 2005. Galanin and spinal nociceptive mechanisms: Recent results from transgenic and knock-out models. Neuropeptides 39:207–210.
   PubMed Web of Science ®Google Scholar
• Wrenn CC, Crawley JN. 2001. Pharmacological evidence supporting a role for galanin in cognition and affect. Progress Neuro-Psychopharmacol Biolog Psychiatry 25:283–299.
   PubMed Web of Science ®Google Scholar
• Zhang L, Robertson CR, Green BR, Pruess TH, White HS, Bulaj G. 2009. Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Medicinal Chem 52:1310–1316.
   PubMed Web of Science ®Google Scholar
• Zini S, Roisin MP, Armengaud C, Ben-Ari Y. 1993. Effect of potassium channel modulators on the release of glutamate induced by ischaemic-like conditions in rat hippocampal slices. Neurosci Lett 153:202–205.
   PubMed Web of Science ®Google Scholar
• von Heijne G. 1989. Control of topology and mode of assembly of a polytopic membrane protein by positively charged residues. Nature 341:456–458.
   PubMed Web of Science ®Google Scholar